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Edited by Lukas HuberAbstract Using high-density oligonucleotide array, we compre-
hensively analyzed expression levels of 12 600 genes in 50 hepa-
tocellular carcinoma (HCC) samples with positive hepatitis C
virus (HCV) serology (well (G1), moderately (G2), and poorly
(G3) diﬀerentiated tumors) and 11 non-tumorous livers (L1 and
L0) with and without HCV infection. We searched for discrimi-
natory genes of transition (L0 vs. L1, L1 vs. G1, G1 vs. G2, G2
vs. G3) with a supervised learning method, and then arranged the
samples by self-organizing map (SOM) with the discriminatory
gene sets. The SOM arranged the ﬁve clusters on a unique sig-
moidal curve in the order L0, L1, G1, G2, and G3. The sample
arrangement reproduced development-related features of HCC
such as p53 abnormality. Strikingly, G2 tumors without venous
invasion were located closer to the G1 cluster, and most G2
tumors with venous invasion were located closer to the G3 cluster
(P = 0.001 by Fishers exact test). Our present proﬁling data will
serve as a framework to understand the relation between the
development and dediﬀerentiation of HCC.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepatocellular carcinoma1. Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers and represents a major international health prob-
lem because the incidence is increasing in many countries [1–3].
Hepatitis B and C virus (HBV and HCV) infections are major
risk factors for HCC [3–5]. Many factors [6–10] such as HBx
protein, HCV core protein, AXIN1, p53, and allele loss on
chromosome 16 are associated with the pathogenesis of
HCC. Despite intense research eﬀorts in this ﬁeld, it remains*Corresponding author.
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doi:10.1016/j.febslet.2004.10.113unclear how HCC develops and how many genes are involved
in the course of development.
It has been suggested that the majority of small, early stage
HCCs are well diﬀerentiated and that tumor advancement,
which is characterized by pathologic features, occurs via dedif-
ferentiation [10–13]. Dediﬀerentiation also occurs in transgenic
mice carrying the HCV core gene [7]. An example of dediﬀer-
entiation is nodule-in-nodule-type HCC (progressed HCC
within early HCC) [10,11,13]. However, it remains unclear
whether dediﬀerentiation is associated with the development
of all HCC cases. A limitation to testing this is the inability
to collect longitudinal samples from a single patient during
the development of HCC. Molecular proﬁling of a population
in which each member is at a diﬀerent stage of diﬀerentiation
might enable us to understand the development of this disease.
To test this and to elucidate the molecular basis of HCC, we
investigated the levels of expression of 12 600 genes in HCV
antibody-positive HCCs of three grades of diﬀerentiation,
non-tumorous livers without HCV infection, and HCV-
infected non-tumorous livers by high-density oligonucleotide
array. With the use of a supervised learning method [14–17],
we proﬁled genes whose expression diﬀered signiﬁcantly be-
tween classes at a diﬀerent stage. We arranged all samples
according to a self-organizing map (SOM) [18,19] with the
most discriminatory gene sets and investigated the develop-
ment of HCC on the basis of dediﬀerentiation.2. Materials and methods
2.1. Samples
We analyzed levels of expression of 12 600 genes in 76 HCC samples
(Supplementary Table) from 76 patients who underwent surgical treat-
ment for HCC at Yamaguchi University Hospital between May 1997
and August 2000. Written informed consent was obtained from all pa-
tients before surgery. The study protocol was approved by the Institu-
tional Review Board for the Use of Human Subjects at the Yamaguchi
University School of Medicine. Among the 76 patients, 50 were sero-
positive for HCV antibody (HCVAb) and seronegative for hepatitis
B virus surface antigen (HBsAg) (Table 1). The remaining 26 were
seronegative for HCVAb. A histopathologic diagnosis of HCC was
made in all cases after surgery by two experienced pathologists. In
the 50 patients with HCV-related HCC, histopathologic examination
based on TNM classiﬁcation of the International Union Againstblished by Elsevier B.V. All rights reserved.
Table 1
Clinocopathologic characteristics per study group of 50 HCV-positive HCCs
Factors Well (G1)a Moderately (G2)a Poorly (G3)a P-value
Sex P = 0.8007
Male 4 24 6
Female 3 11 2
Age (year)b 65.3 ± 7.0 65.4 ± 7.1 67.2 ± 9.5 P = 0.9612 (G1 vs. G2)
P = 0.6595 (G1 vs. G3)
P = 0.5406 (G2 vs. G3)
Primary lesion P = 0.0568
Single tumor 6 15 2
Multiple tumors 1 20 6
Capsule formation P = 0.3339
Present 4 29 6
Absent 3 6 2
Tumor size (cm)b 2.0 ± 0.8 5.0 ± 3.2 6.0 ± 7.0 P = 0.0007 (G1 vs. G2)
P = 0.0279 (G1 vs. G3)
P = 0.6397 (G2 vs. G3)
Stagea P = 0.0656
I 6 10 2
II 1 17 3
IIIA/IV 0 8 3
Microscopic venous invasiona P = 0.0381
() 7 21 3
(+) 0 14 5
Alpha-feto protein (ng/ml) P = 0.1504
<or =100 6 24 3
>100 1 11 5
Non-tumorous liver P = 0.7569
Normal or chronic hepatitis 2 15 2
Liver cirrhosis 5 20 6
Fishers exact test, Students t test and Mann–Whitneys U test were used to elucidate diﬀerences in backgrounds between each group.
aTumor diﬀerentiation, stage, and microscopic venous invasion were determined on the basis of TNM classiﬁcation of UICC (Ref. [20]). G1–G3
tumors are equal to types I–III of Edmondson and Steiner classiﬁcation, respectively.
bMean ± S.D.
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had moderately diﬀerentiated HCC (G2), and the remaining eight
had poorly diﬀerentiated HCC (G3). The degree of tumor diﬀerentia-
tion in all samples was reproducible between the pathologists. Clinico-
pathologic factors were also determined according to TNM
classiﬁcation. Fishers exact test, Students t test, and the Mann–
Whitney U test were used to evaluate diﬀerences in clinicopathologic
characteristics among G1, G2, and G3 tumors. A value of P < 0.05
was considered to be statistically signiﬁcant.
As controls, six non-tumorous liver samples (L0) from six patients
who underwent hepatic resection for benign or metastatic liver tumors
(1 focal nodular hyperplasia, 2 hemanigiomas, and 3 metastatic liver
cancers derived from 2 colon cancers and 1 gastric cancer) and who
had histologically normal livers were used. All control subjects were
seronegative for both HBsAg and HCVAb. We also had ﬁve HCV-
infected non-tumorous liver samples from ﬁve HCC patients. Among
the ﬁve liver samples (L1), 2 were histopathologically diagnosed as
chronic hepatitis and 3 as liver cirrhosis. Informed consent in writing
was obtained from all of these patients before surgery.
2.2. DNA microarray analysis
We divided the resected specimens into two groups immediately
after surgery; one was immediately frozen in liquid nitrogen for
RNA extraction, and the other was ﬁxed in 10% formaldehyde solu-
tion and embedded in paraﬃn. Samples from the latter group were
used to conﬁrm histopathologically that tissues used for RNA extrac-
tion were not necrotic. Extraction of RNA was performed as described
previously [14–17]. In all samples, the quality of extracted RNA wasconﬁrmed by the appearance of characteristic 28S and 18S rRNA frag-
ments on agarose gels. Synthesis of cDNA and cRNA and oligonu-
cleotide microarray screening were performed as described previously
[14–17]. In the present study, huU95A DNA Chips (Aﬀymetrix, San-
ta Clara, CA) [21] containing 12 600 genes were used.
2.3. Gene selection
We ﬁrst selected genes with expression levels >40 (arbitrary units by
Aﬀymetrix) in all 50 HCC samples and 11 non-tumorous liver samples.
This ﬁltering resulted in the identiﬁcation of 3559 genes. We used the
Fisher ratio [14–17] to evaluate the potentials of the selected genes to
discriminate L0 vs. L1, L1 vs. G1, G1 vs. G2, and G2 vs. G3. For each
transition, the 3559 genes were ranked in order of decreasing magni-
tude of the Fisher ratio. To determine the number of genes to be con-
sidered, a random permutation test was performed as described
previously [14–17]. From the distribution of the Fisher ratios based
on randomized data, all genes that passed the random permutation test
(P < 0.005) were selected. We found that the expression levels of 152
genes with Fisher ratios >4.90 between L0 and L1 were statistically sig-
niﬁcant. Likewise, we identiﬁed signiﬁcant discriminatory genes, the
top 191 genes with the Fisher ratios >4.08 between L1 and G1, the
top 54 genes with the Fisher ratios >1.52 between G1 and G2, and
the top 40 genes with the Fisher ratios >1.34 between G2 and G3.
To estimate the percentage of genes identiﬁed by chance in the above
gene selections, the false discovery rate (FDR) was calculated as de-
scribed previously [22]. Permutations were deﬁned as balanced, and
the Fisher ratio for each gene was computed for each of the balanced
permutations. To verify the results provided by the random permuta-
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balanced permutation was computed by counting the number of genes
that exceeded the threshold for the random permutation test. The esti-
mated number of falsely signiﬁcant genes was the average of the num-
ber of genes termed signiﬁcant from all balanced permutations. The
FDR was determined as the ratio of the estimated number of falsely
signiﬁcant genes to the number of genes identiﬁed by the random per-
mutation test.
2.4. Minimum distance classiﬁer
To compare classes, we designed the minimum distance classiﬁer
with the top 40 genes selected in each transition. First, the level of
expression of each gene was normalized to have zero mean and unit
variance with training samples from two classes. To classify a sample,
we measured the Euclidean distance from the sample to each of the
mean vectors and assigned the sample to the grade of the nearest mean
vector.
2.5. Self-organizing map
A SOM is a neural network algorithm that is used widely for cluster-
ing and is an eﬃcient tool for the visualization of multi-dimensional
data [18,19]. We used MATLAB R13 (The MathWorks, Inc. Natick,
MA) with the SOM toolbox 2.0 (http://www.cis.hut.ﬁ/projects/som-
toolbox/) to arrange all samples.3. Results
3.1. Clinicopathologic characteristics of HCV-related HCCs
according to diﬀerentiation grade
The tumor size in G2 and G3 was signiﬁcantly larger than
that in G1 (Table 1) (P = 0.0007 and P = 0.028, respectively,Fig. 1. Genes that discriminate transitions in the development of HCC expres
from L0 (blue) to L1 (pink) (a), 191 genes with signiﬁcantly altered expression
altered expression during transition from G1 to G2 (orange) (c) and 40 gene
(black) (d) are shown in color. Panels e, f, g, and h illustrate expression of
Expression of the 40 genes with signiﬁcantly altered expression in the transitio
40 selected genes for each transition discriminate pre-transition and post-tran
ratio (see Section 2) and are listed as an accession number. Accession numb
www3.ncbi.nlm.nih.gov/PubMed/) or the Institute for Genomic Research
reports.html).by Mann–Whitney U test). None of the seven G1 tumors in-
volved vessels. G2 and G3 tumors involved vessels more fre-
quently than did G1 tumors (P = 0.038 by Fishers exact
test). From G1 to G3, tumor stage tended to be more advanced
(P = 0.066 by Fishers exact test). Thus, HCCs of three grades
of diﬀerentiation showed features characteristic of cancer
development (tumor size, vessel involvement, and tumor stage)
[11,13]. We hypothesized that HCC develops sequentially from
L0 to L1 to G1 to G2 to G3, and we searched for discrimina-
tory genes for the four transitions (L0 to L1, L1 to G1, G1 to
G2, G2 to G3).3.2. Genes selected in each transition of hypothesized
development
Our gene selection procedure identiﬁed 152 genes with
expression levels that diﬀered signiﬁcantly between L0 and
L1. Among these genes, expression of 67 was upregulated
and that of 85 was downregulated in L1 compared to L0
(Fig. 1(a), Table 2, and supplemental tables). Likewise, we
identiﬁed 191 genes with expression levels that diﬀered signiﬁ-
cantly between L1 and G1. Among these genes, expression of
95 was upregulated and that of 96 was downregulated in G1
compared to L1 (Fig. 1(b), Table 3, and supplemental tables).
Among the 54 genes diﬀerentially expressed between G1 and
G2 tumors, expression of 36 genes was increased and that of
18 genes was decreased in G2 compared to G1 (Fig. 1(c), Table
4, and supplemental tables). Among the 40 genes that were dif-
ferentially expressed between G2 and G3 tumors, expression ofsion of 152 genes with signiﬁcantly altered expression during transition
during transition from L1 to G1 (green) (b), 54 genes with signiﬁcantly
s with signiﬁcantly altered expression during transition from G2 to G3
the 40 most discriminatory genes for each transition in all samples.
ns from L0 to L1 (e), L1 to G1 (f), G1 to G2 (g), and G2 to G3 (h). The
sition grade samples. Genes are shown in decreasing order of the Fisher
er of each gene was obtained from PubMed (Internet address: http://
databases (Internet address: http://www.tigr.org/tdb/hgi/searching/
Table 2
Top-40 discriminatory genes in L0 and L1
Fisher ratio GB number Description Symbol Locus Function
Eighteen genes downregulated in L1 in comparison with L0
50.45 M18533 Dystrophin DMD Xp21.2 Cytoskeleton
23.02 AF035316 Homolog to tubulin beta chain 6p24.3 Unknown
20.65 AL049942 Zinc ﬁnger protein 337 ZNF337 20p11.1 Unknown
18.34 L27479 Friedreich ataxia region gene X123 X123 9q13-q21 Unknown
16.63 Fibronectin (Alt. Splice 1) Extracellular matrix
16.13 U19765 Zinc ﬁnger protein 9 ZNF9 3q21 Transcription/retroviral
nucleic acid binding
protein
14.91 X55503 Metallothionein IV MTIV 16q13 Detoxiﬁcation
13.71 AL046394 Poly(rC) binding protein 3 PCBP3 21q22.3 RNA-binding protein/
post-transcriptional
control
12.56 AB007886 KIAA0426 gene product KIAA0426 6p22.2-p21.3 Unknown
12.41 AL050139 Hypothetical protein FLJ13910 FLJ13910 2p11.1 Unknown
12.37 AF012086 RAN binding protein 2-like 1 RANBP2L1 2q12.3 Signal transduction/
small GTP-binding
protein
11.66 AI539439 S100 calcium binding protein A2 S100A2 1q21 Extracellular stimuli and
cellular responses
11.24 M19828 Apolipoprotein B APOB 2p24-p23 Lipid metabolism
10.59 U92315 Sulfotransferase family, cytosolic, 2B, member 1 SULT2B1 19q13.3 Steroid metabolism
10.53 D76444 Zinc ﬁnger protein 103 homolog (mouse) ZFP103 2p11.2 Central nervous system
development
10.50 X02761 Fibronectin 1 FN1 2q34 Extracellular matrix/cell
adhesion and motility
10.20 AF001891 Zinc ﬁnger protein-like 1 ZFPL1 11q13 Unknown
9.74 AI400326 EST 2 UniGene Cluster
Hs.356456
Twenty-two genes upregulated in L1 in comparison with L0
40.49 AI362017 Cystatin C CST3 20p11.21 Cysteine protease
inhibitor
21.66 L13977 Prolylcarboxypeptidase (angiotensinase C) PRCP 11q14 Metabolism/lysosome-
related protein
20.59 D32053 Lysyl-tRNA synthetase KARS 16q23-q24 Protein biosynthesis
13.70 AF038962 Voltage-dependent anion channel 3 VDAC3 8p11.2 Transport of adenine
nucleotides
11.90 AL008726 Protective protein for beta-galactosidase (cathepsin A) PPGB 20q13.1 Lysosomal protein/
enzyme activator
11.71 J03909 Interferon, gamma-inducible protein 30 IFI30 19p13.1 Lysosomal thiol
reductase/IFN-inducible
11.32 Z69043 Signal sequence receptor, delta SSR4 Xq28 Translocatation of newly
synthesized polypeptides
11.17 AL080080 Thioredoxin-related transmembrane protein TXNDC 14q21.3 Redox reaction
11.15 M63138 Cathepsin D CTSD 11p15.5 Lysosomal aspartyl
protease/proteolysis
11.12 L09159 Ras homolog gene family, member A ARHA 3p21.3 Oncogenesis/actin
cytoskeleton
reorganization
10.99 AF017115 Cytochrome c oxidase subunit IV isoform 1 COX4I1 16q22-qter Energy pathway
10.76 M13560 CD74 antigen CD74 5q32 Immune response
10.22 M36035 Benzodiazapine receptor BZRP 22q13.31 Flow of cholesterol into
mitochondria
10.08 U47101 Nitrogen ﬁxation cluster-like NIFU 12q24.1 Unknown
9.70 U81554 Calcium/calmodulin-dependent protein kinase II gamma CAMK2G 10q22 Signal transduction
9.59 M21186 Cytochrome b-245, alpha polypeptide CYBA 16q24 Energy generation
9.47 D32129 Major histocompatibility complex, class I, A HLA-A 6p21.3 Immune response
9.44 AL022723 Major histocompatibility complex, class I, F HLA-F 6p21.3 Immune response
9.41 M83664 Major histocompatibility complex, class II, DP beta 1 HLA-DPB1 6p21.3 Immune response
9.16 U50523 Actin related protein 2/3 complex, subunit 2 ARPC2 13q12-q13 Cell motility and
cytoskeleton
9.02 M81757 Ribosomal protein S19 RPS19 19q13.2 Oncogenesis/RNA-
binding protein
8.89 AF102803 Catenin (cadherin-associated protein), alpha 1 CTNNA1 5q31 Cell adhesion
GB number of each gene was obtained from PubMed (http://www3.nibi.nlm.nih.gov/PubMed/).
Symbol used is based on the data from LocusLink (http://www.nibi.nlm.nih.gov/LocusLink/).
Downregulated genes; Fold change of L1 vs. L0 < 1.
Upregulated genes; Fold change of L1 vs. L0 > 1.
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Table 3
Top-40 discriminatory genes in L1 and G1
Fisher ratio GB number Description Symbol Locus Function
Twenty-eight genes downregulated in G1 in comparison with L1
26.84 M93221 Mannose receptor, C type 1 MRC1 10p13 Phagocytosis and pinocytosis
26.08 AF079221 BCL2/adenovirus E1B 19 kD interacting protein 3-like BNIP3L 8p21 Tumor suppressor/induction
of apoptosis
21.46 V01512 v-fos FBJ murine osteosarcoma
viral oncogene homolog
FOS 14q24.3 Oncogenesis/transcription
21.45 D88587 Ficolin 3 (Hakata antigen) FCN3 1p35.3 Extracellular space
20.15 U12022 Calmodulin 1 CALM1 14q24-q31 Signal transduction/calcium-
binding protein
19.73 AF055376 v-maf musculoaponeurotic ﬁbrosarcoma
oncogene homolog
MAF 16q22-q23 Oncogenesis/transcription
19.19 R93527 Metallothionein 1H MT1H 16q13 Detoxiﬁcation
18.19 R92331 Metallothionein 1E MT1E 16q13 Detoxiﬁcation
17.65 U83460 Solute carrier family 31, member1 SLC31A1 9q31-q32 Copper ion transport
17.30 AF052113 RAB14, member RAS oncogene family RAB14 9q32-q34.11 Ras superfamily member of
GTP-binding proteins
15.26 H68340 RNA helicase-related protein RNAHP 17q22 Alteration of RNA
secondary structure
14.96 M10943 Metallothionein 1F MT1F 16q13 Detoxiﬁcation
14.18 M13485 Metallothionein 1B MT1B 16q13 Detoxiﬁcation
13.34 U75744 Deoxyribonuclease I-like 3 DNASE1L3 3p21.1-3p14.3 DNA metabolism
12.65 X02544 Orosomucoid 1 ORM1 9q31-q32 Immune response/acute-
phase response
11.95 M93311 Metallothionein 3 MT3 16q13 Detoxiﬁcation
11.58 Z24725 Mitogen inducible 2 MIG2 14q22.1 Cell cycle and cell
proliferation
11.52 U22961 Unknown Unknown
11.45 M62403 Insulin-like growth factor binding protein 4 IGFBP4 17q12-q21.1 Signal transduction/cell
proliferation
11.01 M35878 Insulin-like growth factor binding protein 3 IGFBP3 7p13-p12 Signal transduction/cell
proliferation
10.80 U84011 Amylo-1, 6-glucosidase, 4-alpha-glucanotransferase AGL 1p21 Glycogen degradation
10.74 AF055030 PHD zinc ﬁnger protein XAP135, isoform b XAP135 6q27 Unknown
10.29 L13977 Prolylcarboxypeptidase (angiotensinase C) PRCP 11q14 Metabolism/lysosome-
related protein
10.02 D13891 Inhibitor of DNA binding 2 ID2 2p25 Negative regulator of cell
diﬀerentiation
9.95 M63175 Autocrine motility factor receptor AMFR 16q21 Signal transduction/cell
motility
9.94 AB023157 KIAA0940 protein KIAA0940 10q23.33 Unknown
9.76 U20982 Insulin-like growth factor binding protein 4 IGFBP4 17q12-q21.1 Signal transduction/cell
proliferation
9.09 M14058 Complement component 1, r subcomponent C1R 12p13 Immune response
Twelve genes upregulated in G1 in comparison with L1
30.42 AL049650 Small nuclear ribonucleoprotein polypeptides B and B1 SNRPB 20p13 RNA processing/
modiﬁcation/RNA splicing
20.95 U61232 Tubulin-speciﬁc chaperone e TBCE 1q42.3 Microtubule/cochaperonin
11.95 AI991040 DR1-associated protein 1 DRAP1 11q13.3 Transcription
10.96 U64444 Ubiquitin fusion degradation 1-like UFD1L 22q11.21 Proteolysis
10.71 D63997 Golgi autoantigen, golgin subfamily a, 3 GOLGA3 12q24.33 Stabilization of Golgi
structure
10.60 X55503 Metallothionein IV MT4 16q13 Detoxiﬁcation
10.23 AL080181 Immunoglobulin superfamily, member 4 IGSF4 11q23.2 It possess low similarity to
viral receptor
10.01 X76228 aTX1 antioxidant protein 1 homolog (yeast) ATP6V1E 22q11.1 Proton transport
9.77 AB018330 Calcium/calmodulin-dependent protein kinase 2, beta CAMKK2 12q24.2 Signal transduction/calcium-
binding protein
9.41 D76444 Zinc ﬁnger protein 103 homolog (mouse) ZFP103 2p11.2 Central nervous system
development
9.31 U70660 ATX1 antioxidant protein 1 homolog (yeast) ATOX1 5q32 Copper homeostasis and ion
transport
9.10 U10323 Interleukin enhancer binding factor 2, 45 kD ILF2 1q21.1 Transcription
GB number of each gene was obtained from PubMed (http://www3.nibi.nlm.nih.gov/PubMed/).
Symbol used is based on the data from LocusLink (http://www.nibi.nlm.nih.gov/LocusLink/).
Downregulated genes; Fold change of G1 vs. L1 < 1.
Upregulated genes; Fold change of G1 vs. L1 > 1.
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Table 4
Top-40 discriminatory genes in G1 and G2
Fisher ratio GB number Description Symbol Locus Function
Fifteen genes downregulated in G2 in comparison with G1
2.89 M87434 20-50-oligoadenylate synthetase 2 OAS2 12q24.2 Antiviral response
protein/IFN-inducible
2.63 M12963 Class I alcohol dehydrogenase alpha subunit ADH1A 4q21-q23 Detoxiﬁcation
2.51 AI625844 Hypothetical protein FLJ20378 Unknown
2.43 M97936 Signal transducer and activator of transcription 1 STAT1 2q32.2 Transcription/IFN-
signaling pathway
2.12 Z99129 Heat shock transcription factor 2 HSF2 6q22.33 Transcription
2.08 L07633 Proteasome activator subunit1 PSME1 14q11.2 Proteolysis and
peptidolysis/IFN-
inducible
2.06 D50312 Potassium inwardly-rectifying
channel subfamily J, member8
KCNJ8 12p11.23 Potassium transport
2.02 U07364 Proteasome activator subunit1 PSME1 14q11.2 Proteolysis and
peptidolysis/IFN-
inducible
2 AA883502 Ubiquitin-conjugating enzyme E2L6 UBE2L6 11q12 Proteolysis and
peptidolysis
1.85 M97935 Signal transducer and activator of transcription 1 STAT1 2q32.2 Transcription/IFN-
signaling pathway
1.83 AF061258 LIM protein LIM 4q22 Signal transduction
1.74 AB007447 FLN 29 gene product FLN29 12q Signal transduction
1.72 M97935 Signal transducer and activator of transcription 1 STAT1 2q32.2 Transcription/IFN-
signaling pathway
1.7 W28281 GABA(A) receptor-associated protein like 1 GABARAPL1 12p13.1 Microtubule
associated protein
1.66 M97935 Signal transducer and activator of transcription 1 STAT1 2q32.2 Transcription/IFN-
signaling pathway
Twenty-ﬁve genes upregulated in G2 in comparison with G1
4.41 Y00281 Ribophorin I RPNI 3q21.3-q25.2 Protein modiﬁcation/
RNA binding
3.25 D28118 Zinc ﬁnger protein 161 ZNF161 17q23.3 Transcription
2.83 AF104913 Eukaryotic protein synthesis initiation facto
4 gamma
EIF4G1 3q27-qter Translation
2.27 AA675900 Formin binding protein 3 FNBP3 2q23.3 Proteolysis and
peptidolysis
2.27 L27706 Chaperonin containing TCP1, subunit 6A (zeta 1) CCT6A 7p14.1 Chaperone/protein
folding
2.15 D32050 Alanyl-tRNA synthetase AARS 16q22 tRNA processing/
protein synthesis
2.1 M63573 Peptidylprolyl isomerase B PPIB 15q21-q22 Chaperone/immune
response
2.09 AF014398 Inositol(myo)-1(or 4)-monophosphatase 2 IMPA2 18p11.2 Signal transduction
2.08 X70944 Splicing factor proline/glutamine rich SFPQ 1p34.2 mRNA splicing/
mRNA processing
2.03 U70671 Ataxin 2 related protein A2LP 7 Unknown
1.89 AA447263 Golgi reassembly stacking protein 2, 55 kDa GORASP2 2p24.3-q21.3 Golgi stacking
1.87 AB014569 KIAA0669 gene product KIAA0669 3 Unknown
1.85 M23115 ATPase, Ca++ transporting, cardiac muscle,
slow twitch 2
ATP2A2 12q23-q24.1 Small molecule
transport
1.83 D38521 Proteasome activator 200 kDa PA200 2p16.2 Proteolysis and
peptidolysis
1.82 X00351 Actin, beta ACTB 7p15-p12 Cytoskeleton
1.75 L11672 Zinc ﬁnger protein 91 ZNF91 19p13.1-p12 Transcription
1.75 X82834 Golgi autoantigen, golgin subfamily a, 4 GOLGA4 3p22-p21.3 Vesicle transport
1.74 AB007963 KIAA0494 gene product KIAA0494 1pter-p22.1 Unknown
1.74 U76247 Seven in absentia homolog 1 (Drosophila) SIAH1 16q12 Proteolysis and
peptidolysis/
apoptosis
1.73 X68560 Sp3 transcription factor SP3 2q31 Transcription
1.73 AB015344 Ubiquilin 2 UBQLN2 Xp11.23-p11.1 Ubiquitination
1.73 AB018327 Activity-dependent neuroprotector ADNP 20q13.13-q13.2 Unknown
1.7 AF004430 Tumor protein D52-like 2 TPD52L2 20q13.2-q13.3 Cell proliferation
1.67 D14697 Farnesyl diphosphate synthase FDPS 1q21.2 Cholesterol
biosynthesis
1.67 AB028449 Dicer1, Dcr-1 homolog (Drosophila) DICER1 14q32.2 RNA helicase
GB number of each gene was obtained from PubMed (http://www3.nibi.nlm.nih.gov/PubMed/).
Symbol used is based on the data from LocusLink (http://www.nibi.nlm.nih.gov/LocusLink/).
Downregulated genes; Fold change of G2 vs. G1 < 1.
Upregulated genes; Fold change of G2 vs. G1 > 1.
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Table 5
Top-40 discriminatory genes in G2 and G3
Fisher ratio GB number Description Symbol Locus Function
Thirty genes downregulated in G3 in comparison with G2
2.36 AA976838 Apolipoprotein C-I APOC1 19q13.2 Lipid metabolism
2.20 Z11793 Selenoprotein P, plasma, 1 SEPP1 5q31 Antioxidant activity
1.86 AB002311 PDZ domain containing guanine
nucleotide exchange factor 1
PDZ-GEF1 4q32.1 Ras/Rap1A-associating
signal transduction
1.80 Y18004 Sex comb on midleg-like 2 (Drosophila) SCML2 Xp22 Transcription/embryogenesis
and morphogenesis
1.76 AL031230 Aldehyde dehydrogenase 5 family, member A1 ALDH5A1 6p22 Electron transporter/amino
butyrate catabolism
1.71 AF002697 BCL2/adenovirus E1B 19 kD interacting protein 3 BNIP3 14q11.2-q12 Apoptosis
1.65 AB014596 F-box and WD-40 domain protein 1B FBXW1B 5q35.1 Ubiquitination
1.64 U49897 Phenylalanine hydroxylase PAH 12q22-q24.2 Amino acid biosynthesis
1.62 AF070570 Homo sapiens clone 24473 mRNA sequence 4 Unknown
1.59 M80482 Paired basic amino acid cleaving system 4 PACE4 15q26 Cell–cell signalling/proteolysis
1.59 AI263099 FLJ31305 ﬁs or clone LIVER1000104 16 Similar to Rattus
norvegicus kidney-speciﬁc
protein mRNA
1.57 U22961 Unknown Unknown
1.57 Z24725 Mitogen inducible 2 MIG2 14q22.1 Cell cycle control
1.53 U77594 Retinoic acid receptor responder
(tazarotene induced) 2
RARRES2 7q35 Retinoic acid receptor/
retinoic acid-inducible
1.49 L34081 Bile acid Coenzyme A: amino acid N-acyltransferase BAAT 9q22.3 Liver enzyme for glycine
and bile acid metabolisms
1.49 M88458 KDEL endoplasmic reticulum protein retention
receptor 2
KDELR2 7p22.2 Intracellular protein traﬃc
1.48 U68723 Checkpoint suppressor 1 CHES1 14q24.3-q31 Transcription/cell cycle
1.48 X92098 Coated vesicle membrane protein RNP24 12q24.31 Intracellular protein traﬃc
1.44 D10040 Fatty-acid-Coenzyme A ligase, long-chain 2 FACL2 4q34-q35 Fatty acid metabolism
1.43 AB023194 KIAA0977 protein KIAA0977 2q24.3 Unknown
1.42 AF001903 L-3-hydroxyacyl-Coenzyme A dehydrogenase,
short chain
HADHSC 4q22-q26 Mitochondrial enzyme/
energy generation
1.40 X96752 L-3-hydroxyacyl-Coenzyme A dehydrogenase,
short chain
HADHSC 4q22-q26 Mitochondrial enzyme/
energy generation
1.40 AB006202 Succinate dehydrogenase complex, subunit D SDHD 11q23 Mitochondrial protein/
electron transporter
1.37 M75106 Carboxypeptidase B2 CPB2 13q14.11 Proteolysis and peptidolysis
1.37 Y12711 Rogesterone receptor membrane component 1 PGRMC1 Xq22-q24 Liver-rich protein that
binds to progesterone
1.36 D14662 Anti-oxidant protein 2 AOP2 1q23.3 Antioxidant activity/non-
selenium glutathione
peroxidase
1.36 S87759 Protein phosphatase 1A PPM1A 14q23.1 Cellular stress responses
1.36 Z48199 Syndecan 1 SDC1 2p24.1 Cell adhesion and metastasis
1.35 AF088219 Chemokine (C–C motif) ligand 14 CCL14 17q11.2 Cell proliferation
1.35 AA453183 EST Unknown
Ten genes upregulated in G3 in comparison with G2
2.80 D31767 DAZ associated protein 2 DAZAP2 2q33-q34 RNA-binding protein
2.57 AB000095 Serine protease inhibitor, Kunitz type 1 SPINT1 15q13.3 Inhibitor speciﬁc for
HGF activator
2.40 AB006782 Galectin 9 LGALS9 17q11.1 Cell adhesion and metastasis
2.18 M21186 Cytochrome b-245, alpha polypeptide CYBA 16q24 Energy generation
1.96 AB002312 Bromodomain adjacent to zinc ﬁnger domain 2A BAZ2A 12q24.3-qter DNA-binding protein
1.84 U44772 Palmitoyl-protein thioesterase 1 PPT1 1p32 Neuronal maturation
1.77 AI541308 S100 calcium binding protein A13 S100A13 1q21 Extracellular stimuli and
cellular responses
1.53 Z49107 Galectin 9 LGALS9 17q11.1 Cell adhesion and metastasis
1.36 U77735 Pim-2 oncogene PIM2 Xp11.23 Cell proliferation
1.34 M38449 Transforming growth factor, beta 1 TGFB1 19q13.2 Cell growth and adhesion
GB number of each gene was obtained from PubMed (http://www3.nibi.nlm.nih.gov/PubMed/).
Symbol used is based on the data from LocusLink (http://www.nibi.nlm.nih.gov/LocusLink/).
Downregulated genes; Fold change of G3 vs. G2 < 1.
Upregulated genes; Fold change of G3 vs. G2 > 1.
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mors in comparison to G2 tumors (Fig. 1(d) and Table 5).
Interestingly, there was almost no overlap among these dis-
criminatory genes, with exception of 17 (0.39%) of the total437 genes (see supplementary table). FDRs, the percentage
of genes identiﬁed by chance for L0 vs. L1, L1 vs. G1, G1
vs. G2, and G2 vs. G3, were 0%, 0%, 0.24%, and 0.29%,
respectively.
Fig. 2. Validation of the 40 selected genes for each transition in distinguishing diﬀerentiation grade In each transition, the minimum distance
classiﬁer was constructed with the samples from two consecutive diﬀerentiation grades, which are indicated by a black bar, and was applied to
samples in the remaining diﬀerentiation grades. The resulting classiﬁers classiﬁed pre- and post-diﬀerentiation grades of the samples with 92% (46/50)
(a), 98% (48/49) (b), 84% (16/19) (c), and 100% (18/18) (d) accuracies, respectively.
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Assessment of the 61 samples with the 40 genes with the
greatest diﬀerential expression at the L0 to L1, L1 to G1, G1
to G2, and G2 to G3 transitions clearly discriminated samples
staged before and after each transition (Fig. 1(e)–(h)). Thus,
the 40 most discriminatory genes for each transition discrimi-
nated pre-transition samples from post-transition samples. WeFig. 3. Visualization of sample arrangement by SOM (a) Clusters of samples
neighboring cells are typically near each other. (m, n), index of the cell located
livers without HCV infection (L0); IL-XX, samples from HCV-infected non-t
(G1); G2-XXT, samples from moderately diﬀerentiated tumors (G2); G3-X
clearly arranged on a sigmoidal curve in the order L0, L1, G1, G2, and G3. N
G1 tumors and that G2 tumors with venous invasion (red) are located close to
the cell located at the mth row and nth column. The color of the cells indicate
distance. Red cells in the upper area clearly show that non-tumorous live
discriminatory genes.further examined the discriminative power of the 40 genes for
each transition by the minimum distance classiﬁer. In each
transition, the minimum distance classiﬁer was constructed
with samples from two consecutive diﬀerentiation grades (indi-
cated by the black bar in Fig. 2), and it was applied to samples
in the remaining diﬀerentiation grades. The classiﬁer designed
locally with L0 and L1 samples, whereas it classiﬁed correctly. Each cell in the SOM grid corresponds to one cluster. The vectors of
at the mth row and nth column. NL-XX, samples from non-tumorous
umorous livers (L1); G1-XXT, samples from well diﬀerentiated tumors
XT, samples from poorly diﬀerentiated tumors (G3). The samples are
ote that G2 tumors without venous invasion (blue) are located close to
G3 tumors. (b) Distance between neighboring clusters. (m, n), index of
s the distance between the neighboring clusters, and red indicates a long
r and tumor samples are relatively far apart on all of the 40 most
Fig. 4. Tumor size and p53 status on sigmoidal orbit of HCC development. (a) Tumor size. This shows the reproducible relation between tumor size
and diﬀerentiation grade in most samples. Note that there are aberrant cases with small tumor size (G2-27T and G3-21T) during development. (b)
P53 status. When p53 data [17] from 22 HCCs were applied to the sigmoidal curve, most HCCs with wild-type p53 were located within or close to G1
cluster on the sigmoidal curve. In contrast, four of ﬁve HCCs with p53 mutation were located at the most distant point from the three clusters L0, L1,
and G1, verifying our hypothesis that this disease develops sequentially from L0 to L1 to G1 to G2 to G3. NL-XX, samples from non-tumorous
livers without HCV infection (L0); IL-XX, samples from HCV-infected non-tumorous livers (L1); G1-XXT, samples from well diﬀerentiated tumors
(G1); G2-XXT, samples from moderately diﬀerentiated tumors (G2); G3-XXT, samples from poorly diﬀerentiated tumors (G3).
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2(a)). The classiﬁers designed with L1 and G1 samples, G1
and G2 samples, and G2 and G3 samples classiﬁed the remain-
ing samples with 98% (48/49), 84% (16/19), and 100% (18/18)
accuracies, respectively (Fig. 2(b)–(d)). Thus, the 40 selective
genes represent molecular signatures for each transition during
hypothesized development (Fig. 2).3.4. Arrangement of all samples by SOM
We analyzed our data by SOM [18] with the use of all 40
selective genes. The SOM correctly arranged the ﬁve clusters
on a sigmoidal curve in the order L0, L1, G1, G2, and G3
(Fig. 3(a) and (b)). Strikingly, 11 (52%) of 21 G2 tumors
without venous invasion were located closer to the G1 clus-
ter, and 13 (92%) of 14 G2 tumors with venous invasion
were located closer to the G3 cluster (P = 0.001 by Fishers
exact test) (Fig. 3(a)). Thus, the SOM classiﬁed G2 tumors
into two subtypes: tumors with venous invasion and those
without. Given the ﬁnding that tumor sizes in G2 and G3
were signiﬁcantly larger than that in G1 (Table 1), we as-
signed tumor size to the samples on the sigmoidal curve
(Fig. 4(a)). This reproduced the relation between tumor size
and diﬀerentiation grade in most cases; however, tumor size
was not always consistent with dediﬀerentiation. Rather,
even if they belonged to G2 or G3 HCCs, small tumors
(G2-27T and G3-21T) were located closer to the G1 cluster
(Fig. 4(a)). Thus, our sample rearrangement detected aber-
rant samples.
We next applied p53 abnormality data [17] in 22 of the
HCCs to the sigmoidal curve (Fig. 4(b)). Many HCCs with
wild-type p53 were located within or close to G1 cluster. In
contrast, four of ﬁve HCCs with p53 mutation were locatedat the most distant point from the three clusters L0, L1, and
G1. This result was consistent with a previous report that
p53 abnormality is frequent in HCC at late stage [9]. Collec-
tively, these results verify our hypothesis that this disease
develops sequentially from L0 to L1 to G1 to G2 to G3.
3.5. Validation of microarray data by quantitative RT-PCR
To validate the microarray data, we randomly selected 4 dis-
criminatory genes for each transition and analyzed them by
real-time quantitative RT-PCR. The expression patterns of
CD74, IGFBP3, STAT1, and TGFB1 by microarray were
reproduced by real-time quantitative RT-PCR (supplementary
ﬁgures S1 and S2).4. Discussion
Since the introduction of DNA microarray technology
[23,24], the patterns of gene expression associated with HCC
have been described [14–17,25–32]. Among these studies, four
identiﬁed genes related to dediﬀerentiation of HCC [26–29],
and one identiﬁed molecular markers speciﬁc for HCV-related
HCC [30]. More recently, we have used molecular proﬁling to
identify a new class of HCC according to metastatic potentials
[16]. However, even this state-of-the-art technology does not
address the molecular basis underlying the development of
HCC.
According to histologic features at biopsy, Poynard et al.
[33] investigated liver ﬁbrosis progression after HCV infection.
Their elegant work provided insights into the mechanism of
HCV-related liver ﬁbrosis, which is closely related to hepato-
carcinogenesis. Unfortunately, they did not investigate
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at autopsy from the same patients, Sugihara et al. [12] showed
that 9 of 12 tumors, which had been well diﬀerentiated at
biopsy, developed into moderately diﬀerentiated tumors at
autopsy. With the use of resected HCC specimens, Nakashima
et al. [11] proposed that well diﬀerentiated HCCs become pro-
gressively less diﬀerentiated as they enlarge. Nodule-in-nodule-
type HCC may provide a model for the development of HCC.
However, these phenomena do not necessarily explain all as-
pects of the development of HCC. Thus, a new framework is
necessary to better understand the actual development of
HCC. We proﬁled gene expression patterns in a population
in which each member was at a distinct stage of diﬀerentiation
and characterized molecular diﬀerences between distinct clas-
ses. In this viewpoint, there may be a limitation of our present
study in understanding the actual development. Nevertheless,
the arrangement of samples by SOM was consistent with clas-
sical development-related parameters and supports the
hypothesis that this disease develops sequentially from L0 to
L1 to G1 to G2 to G3.
SOMs with gene expression data can calculate the distance
between samples [18]. Our result is intriguing: G2 tumors with-
out venous invasion were located closer to the G1 cluster, and
G2 tumors with venous invasion were located closer to the G3
cluster. This result is consistent with the increased invasiveness
observed during the progression of many malignant tumors
[34]. Genetic abnormality of p53 is a feature of HCC at the late
stage [9]. In support of this, we found that most HCCs with
p53 abnormality were markedly advanced in the sigmoidal
curve. Moreover, the sigmoidal orbit showed that HCCs be-
come progressively less diﬀerentiated as they enlarge. This re-
sult reproduces the development of HCC reported by
Nakashima et al. [11]. Interestingly, two G2 and G3 HCCs
(G2-27T and G3-21T), whose sizes were <2 cm in diameter,
were located closer to the G1 cluster (Fig. 4(a)). Thus, these
two may be aberrant cases that skipped the normal develop-
ment scenario.
Another striking ﬁnding of our study is that the 40 most
discriminatory genes for each transition clearly divided all
samples into pre-transition and post-transition stages
(Fig. 1(e)–(h)). This ﬁnding was veriﬁed mathematically
(Fig. 2). In addition, the ﬁnding that there was almost no over-
lap among the discriminatory genes indicates that their biolog-
ical functions are speciﬁc for each aspect of development from
L0 to L1 to G1 to G2 to G3. This ﬁnding is unique among
microarray studies [26–29] that have identiﬁed many genes re-
lated to the dediﬀerentiation of HCC. Such an altered level of
gene expression in speciﬁc stages may support the multi-step
transformation theory that was proposed initially by Vogel-
stein et al. [35]. In comparison with those studies [26–29], there
were a few genes that overlapped with genes identiﬁed in the
present study. This discrepancy is not surprising and may be
attributable in part to diﬀerences in sample background and
type of microarray and algorithm used. The genes identiﬁed
in this study represent pathways that are common to each
aspect of development of HCV antibody-positive HCC. For
example, levels of expression of many immune response-
related genes, including MHC class I family members (HLA-
A, -C, -E, and -F), MHC class II family (HLA DPB1 and
HLA-DRA), CD74, NK4, and IFI30, were increased in L1
compared to L0. This is reasonable considering that HCV
infection causes chronic inﬂammation [3,4]. Additionally, highlevels of these MHC class I or II genes were found in HCV-re-
lated cirrhotic liver [36].
In the present study, expression of many oncogenesis-re-
lated genes (BNIP3L, FOS, MAF, IGFBP3, and IGFBP4)
was downregulated from L1 to G1. Insulin-like growth factor
binding protein 3 (IGFBP3) induces apoptosis of some types
of cancer cells, and IGFBP4 acts as an inhibitor of IGF-in-
duced cell proliferation. A previous microarray study showed
that levels of IGFBP3 and IGFBP4 transcripts were de-
creased in HCC compared to those in non-tumorous liver
[27]. Chuma et al. [29] showed that IGFBP3 levels were re-
duced in the early component of nodule-in-nodule-type
HCC compared to those in non-tumorous liver. Thus, the
IGF pathway may play an important role in well diﬀerenti-
ated HCC arising from HCV infection. We also found upreg-
ulation of ATOX1 in G1 HCC. On the basis of the result of
a previous report [30], this ﬁnding is likely to be speciﬁc to
HCV-related HCC.
We found that in dediﬀerentiation of G1 to G2, the most
striking event was downregulation of expression of IFN-
related genes (OAS2, STAT1, PSME1, ISGF3G, and PSMB9).
This result is intriguing considering our previous observation
that IFN-related genes are involved in the pathogenesis of
HCV-related HCC and not HBV-associated HCC [14]. Upreg-
ulation of STAT1 expression in HCC cell lines was observed
during diﬀerentiation induced by sodium butyrate [37]. Inter-
estingly, it was shown that HCV Nonstructural 5A (NS5A)
protein attenuated inducible expressions of IFN-related genes
including STAT1 [38]. These reports suggest that these genes
listed here play a speciﬁc role in the pathogenesis of HCV-
related HCC. Downregulation of expression of these IFN-
related genes also reﬂects decreased immune response. This
concept is supported by a previous study [27] showing that sev-
eral immune response-related genes were repressed in G2 and
G3 HCCs compared with G1 HCC.
We observed upregulation of SPINT1, LGALS9, and
TGFB1 and downregulation of SDC1 in G3 compared with
G2. LGALS9 is member of the lectin family, which is in-
volved in cell adhesion, cell growth regulation, immunomod-
ulation, apoptosis, and metastasis. Several galectins are
thought to be involved in cancer cell adhesion [39]. It has
been reported that TGFB1 triggers invasiveness of HCC cells
via a3b1 integrin [40]. Matsumoto et al. [41] reported rde-
creased expression of SDC1 in HCC with high metastatic po-
tential. Given the present ﬁnding that venous invasion is
found in G2 HCC, altered levels of these metastasis-related
genes would increase further the metastatic potential of G3
HCC and would provide additional molecular targets for
HCC treatment.
Our present study focused on HCC with positive HCV
serology. The identiﬁed discriminatory genes were consistent
with the molecular patterns [30,36] of HCV-infected liver dis-
ease. However, we could not exclude the possibility of an oc-
cult HBV infection because of a lack of the data for hepatitis
B virus core antibody and HBV-DNA in our cohort. This
dilemma prompted us to examine how the discriminatory
genes are involved in HCC with negative HCV serology. We
found that the SOM with the discriminatory gene set failed
to arrange correctly the samples of 26 HCCs with negative
HCV serology (supplementary ﬁgure S3). This striking ﬁnding
suggests that changes in our identiﬁed discriminatory genes
are speciﬁc for HCC with positive HCV serology.
N. Iizuka et al. / FEBS Letters 579 (2005) 1089–1100 1099Because the prognosis of HCC is extremely poor even when
curative surgery is performed [2,3,16], the greatest impact on this
disease will be prevention. A primary strategy of prevention of
transfusion-related HCV infection has almost been achieved,
and a current focus is to prevent the development of HCC in
HCV infection. Currently, oilgonucleotide arrays representing
the whole known genes (about 38 000 genes) are available [42].
In this regard, our proﬁling data may be less informative; how-
ever, these provide additional biomarkers andmolecular targets
for the prevention, diagnosis, and treatment of this disease. The
sigmoidal orbit constructed here may provide a framework to
explain the development of HCC with positive HCV serology.
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